Zydus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 800.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 740.00 Cr
as on 24-10-2024
- Company Age 4 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 1206.77%
(FY 2023)
- Profit -987.22%
(FY 2023)
- Ebitda -168.18%
(FY 2023)
- Net Worth -108.25%
(FY 2023)
- Total Assets 61.47%
(FY 2023)
About Zydus Pharmaceuticals
The Corporate was formerly known as Alidac Healthcare Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 800.00 Cr and a paid-up capital of Rs 740.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Zydus Pharmaceuticals Limited India are Jignesh Thosani as CFO and Dhavlal Soni as Company Secretary. Mukund Thakkar, Prashant Sharma, Vishal Shah, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290GJ2019PLC111689
- Company No.
111689
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2019
- Date of AGM
06 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Zydus Pharmaceuticals?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jignesh Thosani | CFO | 25-May-2020 | Current |
| Dhavlal Soni | Company Secretary | 25-May-2020 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishal Shah  | Whole-Time Director | 25-May-2020 | Current |
| Prashant Sharma | Director | 26-Dec-2019 | Current |
| Mukund Thakkar | Director | 26-Dec-2019 | Current |
| Sujatha Rajesh | Director | 05-Jun-2024 | Current |
| Chimanlal Patel | Director | 26-Dec-2019 | Current |
Financial Performance and Corporate Structure Insights of Zydus Pharmaceuticals.
Zydus Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1206.77% increase. The company also saw a substantial fall in profitability, with a 987.22% decrease in profit. The company's net worth observed a substantial decline by a decrease of 108.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zydus Pharmaceuticals?
In 2023, Zydus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zydus Animal Health And Investments LimitedActive 6 years 7 monthsChimanlal Patel is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zydus Pharmaceuticals?
Unlock and access historical data on people associated with Zydus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zydus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zydus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
